ISPOR - Analysis of Cost Minimization of Adalimumab Compared With Infliximab for The Treatment of Ulcerative Colitis In The Public Market In Mexico

Full Text

Analysis of Cost Minimization of Adalimumab Compared With Infliximab for The Treatment of Ulcerative Colitis In The Public Market In Mexico

Abstract

Authors

CA Pichardo-Piña JL Sanchez-Casillas

Back to Volume 18, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now